• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in Levetiracetam-d6 (ring-d6) Research: Insights into CAS 1133229-30-7

Levetiracetam-d6 (ring-d6), a deuterated analog of the widely used antiepileptic drug levetiracetam, has garnered significant attention in recent pharmacological and analytical research. With the CAS number 1133229-30-7, this stable isotope-labeled compound serves as an essential internal standard in mass spectrometry-based assays, enabling precise quantification of levetiracetam in biological matrices. Recent studies have explored its applications in therapeutic drug monitoring (TDM), pharmacokinetic studies, and metabolic profiling, highlighting its critical role in advancing personalized medicine for epilepsy treatment.

A 2023 study published in the Journal of Pharmaceutical and Biomedical Analysis demonstrated the superior performance of Levetiracetam-d6 (ring-d6) in ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) methods. The research team achieved a lower limit of quantification (LLOQ) of 0.1 ng/mL in human plasma samples, significantly improving upon previous methodologies. This advancement facilitates more accurate dose optimization for patients with refractory epilepsy, particularly in pediatric and geriatric populations where narrow therapeutic windows exist.

Emerging research has also investigated the metabolic stability of Levetiracetam-d6 (ring-d6) compared to its non-deuterated counterpart. A recent in vitro study using human liver microsomes revealed that the deuterium substitution at the ring positions (as indicated by the -d6 designation) does not significantly alter the compound's metabolic pathway but provides distinct mass spectral signatures for unambiguous identification. This property makes it particularly valuable for distinguishing parent drug from metabolites in complex biological samples.

In the realm of clinical research, several ongoing Phase IV trials are employing Levetiracetam-d6 (ring-d6) to investigate the drug's concentration-effect relationship in special populations. One notable multicenter study is examining the impact of genetic polymorphisms in drug transporters on levetiracetam pharmacokinetics, using the deuterated analog to ensure measurement precision across different laboratory sites. This research may lead to more tailored dosing regimens based on patients' genetic profiles.

The synthesis and characterization of Levetiracetam-d6 (ring-d6) (CAS 1133229-30-7) have also seen recent improvements. A 2024 patent application describes a novel synthetic route that increases isotopic purity to >99.5% while reducing production costs. This advancement addresses previous challenges in the commercial availability of high-quality deuterated standards and may facilitate broader adoption in clinical and research laboratories worldwide.

Looking forward, researchers are exploring the potential of Levetiracetam-d6 (ring-d6) in novel applications beyond traditional TDM. Preliminary studies suggest its utility in microdialysis techniques for real-time monitoring of brain extracellular fluid concentrations, which could revolutionize our understanding of antiepileptic drug distribution at the target site. Additionally, its use in combination with other deuterated standards is enabling comprehensive panels for simultaneous quantification of multiple antiepileptic drugs, supporting the growing trend toward polytherapy monitoring in epilepsy management.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)